Background: Glioblastoma multiforme (GBM) is the most aggtessive primary brain tumor in adultswith dismal prognosis due to the unavailability of an effective therapy. Up to now, there had been no definitive studies published on EGFR inhibition therapy as a chemosensitizer for GBM therapy using Temozolomide (TMZ). This study aims to reveal the most effective method and timing to administerTMZ-anti EGFR targeted therapy which causes maximal DNA damage on GBM cells.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most frequently found and most aggressive glial cell tumor, associated with a dismal prognosis and mean survival time of one year after diagnosis.r '2 This poor prognosis is caused by our incomplete understanding on this aggressive tumor's characteristics and the lack of an effective therapy.
The standard chemotherapy agent for GBM is Temozolomide (TMZ). 3 Many studies have been performed to overcome TMZ resistance, including modifications to administration dosage and mechanism, and the combination of TMZ with other agents or targeted therapies. Currently available targeted therapy for GBM include PI3-IVmTOR, PDGFR After 24 hours, the other duplet had its medium aspirated dry, harvested by submerging with 0.1% trypsin [Gibco] for 5 minutes at 37C. Cells from each well then were suspended in 500 pl PBS and analyzed by flow cytometry as separate samples: the whole 500 pl PBS of each sample was run through flow cytometer and had its approximate total cell number recorded by the program. Optimal drug concentration was also determined by these cell numbers.
U87MG drug treatment
Cells were planted 3 days prior to Nimotuzumab (NMZ) and Temozolomide (TMZ) treatments, on 3xl2-wells plates, submerged in growth medium. Then on the third day, cells were treated with 8 different treatments. 4 wells were allocated for each of these treatment groups: Nontreated (Control), NMZ only for 72h (N), TMZ only for 72h (T), NMZ and TMZ for 72h (NT), NMZ after T4tTMZ (N24T), NMZ after 48hTMZ (N48T), TMZ after 24h NMZ (T24N), and TMZ after 48h NMZ (T48N). NMZ was given at 1000 pglml and TMZ at 20 pg/ml in their respective treatment groups, both based optimal drug concentration determined beforehand. The rest 4 wells were reserved as spare wells in case anything unexpected happened to any of the allocated wells prior to cell treatment, to ensure the cells within all B ali/ 14 edirA.lu J ou.,r na.],, ( g aU M e D 20 I 5, V olrume 4, N um)se,r 3 : I 0 9 -I I 3 P-ISSN.2089 -r r 80, r-ISSN.2302 -297+ wells to be treated were in possible best conditions and closest to identical numbers. Unused spare wells were later on used as flow-cvtometrv unlabeled control.
U87MG flow cytometry
After 72 hours of treatments, cells were harvested by submerging with 0.1% trypsin [Gibco] for 5 
Statistical analysis
Statistical analysis was performed using the SPSS for Windows, version 21.0. The significance of differences between groups was compared using One Way Anova. The significance of differences in groups was compared using LSD. Differences were considered significant ifp < 0.05.
RESULTS
The results of flowcytometer examination of each treatment was presented in table and graph Open access: www.balimedicaliournal.org and www.ois.unud.ac.id tsal,i/ l4edirA'l/Jor'wy'tdt (Bal,t MAD 2075, Vol*tnet 4, Nwvdser 3: 709 -773 P-ISSN.208 9 - -Similar drug administration order, with different administration interval, was shown to have a different effect; T24N has higher yH2AX levels than T48N, and N24T has higher yH2AX levels than N48T. This indicates that the timing of administration has an effect on the increased DNA damage mechanism. This study shows that the administration of Temozolomide or Nimotuzumab within 24 hours before the next drug can increase DNA damage compared to 48 hours' This is thought to be caused by a very fast reaction phase by tlie defensive mechanism of GBM cells towards radiochemotherapy; within l-4 hours of drug administration, intranuclear EGFR translocation and DNA-PK already begins to repair th^e DNA damage caused by Temozolomide'' The administration of Nimotuzumab within the first 24 hours is effective in inhibiting the DNA repair process, while Temozolomide continues to .cause bNA du.ug. and DNA double strain breaks'r6 The administration of Nimotuzumab in the first 24 hours will inhibit the interaction and activity of EGFR-DNA-PK enzyme, increasing DNA damage in vitro. The inhibition of DNA repair through the main NHEJ PathwaYs bY EGFR-DNA PK interaction will increase the ability of Temozolomide in causing damage to GBM cell DNA.
CONCLUSION
The administration of Nimotuzumab, concunently or within 24 hours before the administration of Temozolomide. is an effective combination in maximizing DNA damage to the DNA of GBM cells in vitro. The initial inhibition of DNA repair enzymes (DNA PK) through the mechanism of EGFR blockage will synergize with the effects of Temozolomide in causing DNA damage.
